Zepbound vs Wegovy: Which Is Better, and How Do They Differ?

Zepbound vs Wegovy (or Wegovy vs Zepbound) is the comparison most people make before choosing a weekly weight-loss shot. SURMOUNT-5 is the only published head-to-head trial of the two at weight-loss doses that we found. In it, people on Zepbound lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% on Wegovy (semaglutide up to 2.4 mg). Wegovy, though, has approved uses Zepbound does not (lowering heart attack and stroke risk, treating a liver disease called MASH, and treating teens with obesity), and it also comes as a daily pill.

Both injections are once-weekly medicines that act on the GLP-1 hormone receptor, and both share a similar set of digestive side effects, covered in detail in our page on Zepbound side effects. This guide compares Zepbound vs Wegovy using the current FDA labels (Wegovy revised 06/2026, Zepbound revised 08/2026) and the published trials.

In this guide you will learn:

• How each medicine works and what the head-to-head trial found
• Which conditions each label covers, and which it does not
• Doses, devices, and the Wegovy pill in brief
• Side effects from each label and from the same trial, side by side
• Label differences women should know, prices as of September 2026, and how switching works

Table of Contents

• Wegovy vs Zepbound at a glance
• How Wegovy and Zepbound work
• Which works better? The SURMOUNT-5 head-to-head trial
• Approved uses: what each label covers
• Forms and doses: pens, vials, and the Wegovy pill
• Wegovy vs Zepbound side effects
• Label differences women should know
• Wegovy vs Zepbound cost and insurance
• Switching from Wegovy to Zepbound (or back)
• Which one might fit you?
• Eating well on Wegovy or Zepbound
• Key takeaways
• Frequently asked questions

Wegovy vs Zepbound at a Glance

Wegovy vs Zepbound comes down to one hormone target against two, different approved uses, and different prices. Zepbound produced more weight loss in the head-to-head trial, while Wegovy covers more conditions and also comes as a pill. For every approved GLP-1 medicine side by side, see our GLP-1 medications list.

Sources: Wegovy and Zepbound Prescribing Information; Aronne et al., NEJM 2025; manufacturer price pages checked September 24, 2026. Separate label trials are not head-to-head.

How Wegovy and Zepbound Work

Zepbound (tirzepatide) activates two gut-hormone receptors, GIP and GLP-1, while Wegovy (semaglutide) activates only the GLP-1 receptor. Both reduce appetite, and both stay in the body long enough for one shot a week.

• Wegovy: the label (section 12.1) describes semaglutide as a GLP-1 analogue with 94% sequence similarity to the body's own GLP-1. Its half-life is about 1 week.
• Zepbound: the label (section 12.1) calls tirzepatide "a GIP receptor and GLP-1 receptor agonist" and notes that, in nonclinical studies, the added GIP action may further contribute to the regulation of food intake. Its half-life is about 5 days.

The dual action is the main scientific difference, but the labels do not claim it explains the larger weight loss in the head-to-head trial. The same two molecules also have diabetes brands: tirzepatide is sold as Mounjaro, and semaglutide as Ozempic (injection and tablets) and Rybelsus (tablets). Our Zepbound vs Mounjaro comparison explains how the two tirzepatide brands differ.

Which Works Better? The SURMOUNT-5 Head-to-Head Trial

On Zepbound vs Wegovy weight loss, SURMOUNT-5 gives the clearest answer: Zepbound's active ingredient produced an average loss of 20.2% of body weight vs 13.7% for Wegovy's after 72 weeks. Reported in the New England Journal of Medicine in 2025, it is the only published head-to-head trial of the two at weight-loss doses that we found.

How the trial worked:

• 751 adults with obesity, or overweight with a weight-related condition, and no type 2 diabetes.
• Open-label: participants and doctors knew which drug each person took.
• Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly.
• Funding: Eli Lilly, the maker of Zepbound, sponsored the trial.

Waist size fell by 18.4 cm with tirzepatide vs 13.0 cm with semaglutide. In pounds, the average loss was about 50 lb vs 33 lb (22.8 kg vs 15.0 kg), according to the American College of Cardiology's summary of the paper.

Source: ClinicalTrials.gov NCT05822830 results. The journal paper may use a different analysis, so small differences are possible.

Keep the limits in mind. The open-label design and company funding can shape results, and the trial excluded people with diabetes. It also did not test the newer Wegovy options.

What has not been compared

We found no head-to-head trial of Zepbound vs Wegovy HD (7.2 mg) or vs the Wegovy pill. The only way to set them side by side is through separate placebo-controlled trials, which enrolled different people and cannot be compared directly.

Sources: Zepbound Prescribing Information Table 2; Wegovy Prescribing Information Tables 8, 11, and 12.

An earlier trial in type 2 diabetes, SURPASS-2, compared tirzepatide 5, 10, and 15 mg with semaglutide 1 mg (an Ozempic dose, not a Wegovy dose) over 40 weeks. People on tirzepatide lost 1.9 to 5.5 kg more. Wegovy has also been tested head to head against the daily shot Saxenda; our page on Saxenda vs Wegovy has the STEP 8 results.

Approved Uses: What Each Label Covers

Wegovy has three approved uses and Zepbound has two, and only weight management overlaps. Wegovy adds heart risk reduction and MASH, while Zepbound adds obstructive sleep apnea (OSA).

Both labels say the medicine works alongside a reduced-calorie diet and more physical activity. The trials behind the extra uses:

• Heart (Wegovy, SELECT): the trial enrolled 17,604 adults aged 45 or older with heart disease and no diabetes. Major heart events occurred in 6.5% on Wegovy vs 8% on placebo over a median of 41.8 months (hazard ratio 0.80).
• MASH (Wegovy, ESSENCE): at 72 weeks, MASH resolved without worse scarring in 63% vs 34% on placebo, and scarring improved in 37% vs 22%. Continued approval may depend on a confirmatory trial.
• Sleep apnea (Zepbound, SURMOUNT-OSA): at 52 weeks, breathing interruptions fell by 25.3 events per hour vs 5.3 on placebo in people not using PAP. In people using PAP, they fell by 29.3 vs 5.5.

Zepbound's own heart outcomes trial in obesity, SURMOUNT-MMO, is still running, with primary completion estimated for October 2027. According to the FDA approval letter, the August 2026 Zepbound label update added data from a heart outcomes trial in type 2 diabetes (SURPASS-CVOT) to its diabetic eye disease warning; it did not add a heart indication.

Forms and Doses: Pens, Vials, and the Wegovy Pill

Both injections start low and step up every 4 weeks, but Wegovy starts at 0.25 mg and usually stops at 2.4 mg, while Zepbound starts at 2.5 mg and tops out at 15 mg. The milligram numbers are not comparable, since the two molecules differ.

Devices:

• Wegovy: single-dose pens (0.25, 0.5, 1, 1.7, and 2.4 mg, plus 7.2 mg as Wegovy HD) and single-dose syringes. The FlexTouch pen holds four 2.4 mg doses and lasts up to 56 days after first use.
• Zepbound: single-dose pens and single-dose vials from 2.5 to 15 mg, plus a multi-dose vial and the KwikPen, each holding 4 weekly doses. See our Zepbound KwikPen guide for how the pen works.
• Never share a FlexTouch pen or KwikPen, even with a new needle; both labels include this warning.

Injection sites differ slightly. Wegovy can go in the stomach, thigh, or upper arm. Zepbound goes in the stomach or thigh, and the back of the upper arm only when another person gives the shot; see our page on Zepbound injection sites for a rotation plan.

Sources: Wegovy Prescribing Information sections 2.2 and 2.4; Zepbound Prescribing Information sections 2.1 to 2.3. Your prescriber sets your dose and schedule.

Our tirzepatide dosage chart lists every Zepbound step.

The Wegovy pill. Wegovy tablets gained FDA approval on December 22, 2025, for weight reduction and heart risk reduction in adults. You take one each morning on an empty stomach with up to 4 ounces (half a cup) of plain water and swallow it whole. Then wait at least 30 minutes before food, drinks, or other oral medicines. Our page on how to take the Wegovy pill covers each step of the routine. The dose rises every 30 days from 1.5 mg to 4, 9, and then 25 mg. The 25 mg tablet produced a 13.6% average weight loss at 64 weeks vs 2.4% on placebo. Our Wegovy pill vs injection comparison sets the tablet against the weekly shot. Zepbound has no pill form. Lilly's daily pill Foundayo (orforglipron) is a different molecule; see Foundayo vs Zepbound.

Wegovy vs Zepbound Side Effects

Wegovy and Zepbound share the same main side effects: nausea, diarrhea, vomiting, constipation, and stomach pain, mostly while the dose is rising. In SURMOUNT-5, nausea affected about 44% of people on each drug, vomiting and reflux were reported less often with tirzepatide, and injection site reactions more often.

SURMOUNT-5 is the only published trial we found that measured side effects of both drugs at weight-loss doses in the same study.

Source: ClinicalTrials.gov NCT05822830. These are reported counts without statistical testing, so treat small gaps as uncertain.

Stopping the drug because of digestive side effects happened in 2.7% on tirzepatide vs 5.6% on semaglutide, as reported in the NEJM paper and summarized by the American College of Cardiology.

Each label also lists side effects from its own placebo-controlled trials. The trials differed in design and population, and the labels warn that rates from one drug's trials cannot be directly compared with another's. Placebo nausea alone was 16% in the Wegovy trials and 8% in the Zepbound trials.

Sources: Wegovy Prescribing Information Table 3 (up to 68 weeks); Zepbound Prescribing Information Table 1 (up to 72 weeks).

More label numbers worth knowing:

• Stopping for side effects: 6.8% on Wegovy 2.4 mg vs 3.2% on placebo; 4.8% to 6.7% on Zepbound vs 3.4% on placebo.
• Severe digestive reactions: 4.1% on Wegovy injection vs 0.9%; 1.7% to 3.1% on Zepbound vs 1%.
• Wegovy HD (7.2 mg): dysesthesia, a change in skin sensation, affected 22% vs 6% on 2.4 mg and 0% on placebo; nausea reached 39% and vomiting 22%.
• Heart rate: Wegovy lists a heart rate increase (average 1 to 4 beats per minute) as a warning; Zepbound lists an increase of 1 to 3 beats per minute among its adverse reactions.

Serious warnings on both labels

Both labels carry the same core warnings:

• A boxed warning about thyroid C-cell tumors seen in rodents; do not use either drug with a personal or family history of medullary thyroid carcinoma or MEN 2
• Inflammation of the pancreas (pancreatitis): stop the medicine and call your healthcare provider right away if you have severe stomach pain that will not go away, with or without nausea or vomiting
• Gallbladder problems, including gallstones: call your healthcare provider right away if you have pain in your upper stomach, fever, yellowing of skin or eyes, or clay-colored stools
• Low blood sugar when combined with insulin or a sulfonylurea
• Kidney injury from dehydration after vomiting or diarrhea
• Severe digestive reactions; neither drug is recommended in severe gastroparesis
• Serious allergic reactions: stop the medicine and get medical help right away
• Diabetic eye disease complications in people with type 2 diabetes
• Risk of breathing food into the lungs during anesthesia or deep sedation, so tell your care team you take it

Both labels removed the suicidal behavior and ideation warning in early 2026 (Wegovy 01/2026, Zepbound 02/2026). For timing, tips, and when to call a doctor, see our page on Zepbound side effects.

Label Differences Women Should Know

The Wegovy and Zepbound labels differ for women in three ways: birth control pills (Zepbound), planning a pregnancy (Wegovy), and breastfeeding (Wegovy pill). None of them makes one drug safer overall; they change what you plan with your prescriber.

• Birth control pills: the Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. This advice appears on Zepbound's label but not on Wegovy's.
• Planning a pregnancy: the Wegovy label says to stop Wegovy at least 2 months before a planned pregnancy, because semaglutide stays in the body a long time. This applies to weight or heart use, and to MASH when the potential risk outweighs the benefit. The Zepbound label has no similar planning window.
• Pregnancy: both labels say to stop when pregnancy is recognized (Wegovy for weight or heart use), so this is not a difference.
• Breastfeeding: the label does not recommend Wegovy tablets while breastfeeding.

One trial finding, not a label difference: in SURMOUNT-5, weight loss was about 6% lower in men than in women on both drugs, according to the American College of Cardiology's summary of the paper.

If you use birth control pills or plan a pregnancy in the next year, raise it before your first dose of either medicine.

Wegovy vs Zepbound Cost and Insurance

As of September 24, 2026, Wegovy injection costs $349 a month self-pay for most doses, and the Zepbound KwikPen costs $299 to $699 a month depending on the dose. The Wegovy pill starts at $149, and Medicare's GLP-1 Bridge offers a $50 monthly copay for Wegovy and for the Zepbound KwikPen.

Sources: NovoCare Pharmacy Wegovy page and Zepbound savings page. The Zepbound per-dose prices are for the KwikPen; for vials, Lilly lists self-pay starting at $299. The $449 offer applies to the 7.5 to 15 mg KwikPen only: it starts with the first purchase and continues if each refill comes within 45 days of delivery. Prices change often.

With commercial insurance: both makers offer savings cards. Wegovy's can bring the cost down to as little as $25 a month, with savings capped at $100 a month. Zepbound's covers single-dose pen fills for as little as $25, capped at $1,300 per calendar year, and expires December 31, 2026. People with government insurance cannot use either card. Our Zepbound savings card guide explains the caps and the KwikPen options.

With Medicare: the Medicare GLP-1 Bridge runs from July 1, 2026, to December 31, 2027, with a $50 monthly copay. Key points from the Medicare fact sheet:

• It covers Wegovy injection or tablets and the Zepbound KwikPen only; Zepbound single-dose pens and vials do not qualify. Foundayo is also included.
• You need Part D and must be 18 or older. The BMI rules are 35 or more; or 30 or more with certain heart failure, hard-to-control high blood pressure, or chronic kidney disease stage 3a or higher; or 27 or more with prediabetes or a past heart attack, stroke, or blocked arteries in the legs or arms.
• It does not apply if your plan already covers a GLP-1 drug for you, or if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease; contact your plan instead.
• Your prescriber submits a form, and the $50 does not count toward your deductible or out-of-pocket limit.

Commercial coverage depends on the plan. Some plans may cover Wegovy for heart risk or Zepbound for sleep apnea even when they exclude weight-loss drugs, so check your plan's rules for your specific diagnosis. See what insurance covers Zepbound for more on coverage. Compounded semaglutide and tirzepatide are not FDA-approved versions of Wegovy or Zepbound. Our page on compounded tirzepatide explains its legal status.

Switching From Wegovy to Zepbound (or Back)

You can switch from Wegovy to Zepbound, or from Zepbound to Wegovy, but only under your prescriber's direction, because neither FDA label includes a conversion between the two brands. We do not publish a Wegovy to Zepbound dose conversion chart for that reason.

What the labels do say:

• Zepbound: the starting dose "for all indications is 2.5 mg," with no separate start for people coming from another medicine.
• Wegovy: the injection starting dose is 0.25 mg for all uses (tablets start at 1.5 mg). Its only switching rules cover Wegovy injection to Wegovy tablets and back.
• No overlap: both labels say not to use the medicine with any other GLP-1 receptor agonist, so never take Wegovy and Zepbound together.
• Gaps matter: the Wegovy label says to restart escalation at a lower dose after 2 or more missed doses in a row.
• New device, new training: both labels call for training whenever your presentation changes.

Your prescriber decides when to start the new medicine and at which dose. Questions to bring to that visit:

1. When should my first dose of the new medicine be, relative to my last dose of the old one?
2. Which starting dose will I use, and how fast will we step up?
3. What should I do if nausea or vomiting returns after the switch?
4. Does my plan cover the new medicine, and does it need prior authorization?
5. Which device will I get, and who will show me how to use it?

Which One Might Fit You?

There is no single winner in Zepbound vs Wegovy; the labels point toward one or the other in specific situations. The table maps common situations to what each label or trial says, as a starting point for a talk with your prescriber, not a recommendation.

Cost, coverage, side effects you had before, and how you feel about injections also matter. Your prescriber can weigh them with your full history.

Eating Well on Wegovy or Zepbound

On Wegovy or Zepbound, smaller meals built around protein help you meet your nutrition needs while appetite is low. What you eat does not change how the medicine works, but it shapes how much of the weight you lose comes from muscle.

In a SURMOUNT-1 body composition substudy, about a quarter of the weight lost was lean mass, the same share seen with placebo. A 2025 joint nutrition advisory notes that 1.2 to 1.6 grams of protein per kilogram of body weight per day have been proposed during active weight loss. The right body weight to use is unsettled, and strength training is also needed to protect muscle.

Simple habits that help:

• Lead with protein at each meal, such as eggs, fish, chicken, beans, lentils, tofu, or Greek yogurt.
• Plan smaller portions, since both drugs reduce appetite, and add vegetables and whole grains for fiber.
• Keep sipping fluids through the day, since smaller meals can mean less fluid from food.

If you want high-protein recipes and meal ideas sized for a smaller appetite, see our GLP-1 meal plan and protein guide.

Key Takeaways

• Weight loss: SURMOUNT-5 is the only published head-to-head trial of the two at weight-loss doses we found. Zepbound's active ingredient led to 20.2% average loss vs 13.7% with Wegovy's (up to 2.4 mg) at 72 weeks.
• Approved uses: Wegovy also covers heart risk reduction, MASH, and teens 12 and older; Zepbound also covers sleep apnea.
• Side effects: both cause similar digestive effects; in SURMOUNT-5, vomiting was less common and injection site reactions more common with tirzepatide.
• Label differences: Zepbound adds birth control pill advice; Wegovy says to stop 2 months before a planned pregnancy.
• Switching: no conversion chart exists in either label, and the two should never be combined.
• Safety: for signs of a serious allergic reaction on either drug, such as swelling of the face, lips, tongue, or throat or trouble breathing, stop the medicine and get medical help right away.

The Zepbound vs Wegovy choice depends on your health conditions, coverage, and preferences as much as on the trial numbers. Bring this comparison to your prescriber to decide together.

Frequently Asked Questions

Is Zepbound better than Wegovy for weight loss?

SURMOUNT-5 is the only published head-to-head trial of the two at weight-loss doses that we found. In it, people on Zepbound lost an average of 20.2% of body weight at 72 weeks vs 13.7% on Wegovy (semaglutide up to 2.4 mg). Wegovy has uses Zepbound lacks, such as heart risk reduction and MASH, so better depends on your health needs.

Are Wegovy and Zepbound the same thing?

No. Wegovy contains semaglutide, which acts on the GLP-1 receptor. Zepbound contains tirzepatide, which acts on both the GIP and GLP-1 receptors. They come from different makers and have different approved uses.

Can you switch from Wegovy to Zepbound?

Yes, with your prescriber. Neither label has a conversion chart, and the Zepbound label lists 2.5 mg as the starting dose for all uses. Never take the two together.

Is there a Wegovy to Zepbound dose conversion chart?

No. Neither FDA label contains a dose conversion between Wegovy and Zepbound, so any conversion chart you see online is not from the labels. Your prescriber decides the starting dose.

Which has worse side effects, Wegovy or Zepbound?

Both cause similar digestive side effects. In SURMOUNT-5, nausea was reported by about 44% in both groups, vomiting was less common with Zepbound (15.0% vs 21.3%), and injection site reactions were more common (8.6% vs 0.3%).

Which is cheaper, Zepbound or Wegovy?

As of September 24, 2026, Wegovy injection self-pay is $349 a month for most doses. The Zepbound KwikPen is $299 to $699 depending on dose, or $449 for 7.5 mg and up with on-time refills, and Zepbound vials start at $299. The Wegovy pill starts at $149.

Does Medicare cover Zepbound or Wegovy?

The Medicare GLP-1 Bridge, running July 1, 2026 to December 31, 2027, offers eligible Part D enrollees a $50 monthly copay for Wegovy injection or tablets and for the Zepbound KwikPen only. People with moderate to severe sleep apnea, fatty liver disease, or type 2 diabetes are not eligible for the Bridge; Medicare says their drug plan may already cover a GLP-1 drug, so check with the plan.

Can you take Zepbound and Wegovy together?

No. Both labels say not to use them with any other GLP-1 receptor agonist, and that includes each other.

Why do people switch from Wegovy to Zepbound?

Common reasons include the larger average weight loss in SURMOUNT-5, side effects, insurance coverage, price, or a new need such as sleep apnea. The decision and timing belong to your prescriber.

References

1. Wegovy (semaglutide) injection and tablets Prescribing Information, revised 06/2026: Novo Nordisk
2. Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
3. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med, 2025
4. SURMOUNT-5 results, study NCT05822830: ClinicalTrials.gov
5. SURMOUNT-5 journal scan, July 2025: American College of Cardiology
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med, 2021
7. SURMOUNT-MMO, study NCT05556512: ClinicalTrials.gov
8. Drugs@FDA: Wegovy injection, NDA 215256: U.S. Food and Drug Administration
9. Drugs@FDA: Wegovy tablets, NDA 218316: U.S. Food and Drug Administration
10. Drugs@FDA: Zepbound, NDA 217806: U.S. Food and Drug Administration
11. Wegovy pricing, NovoCare Pharmacy: Novo Nordisk
12. Zepbound savings and self-pay pricing: Eli Lilly
13. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month, fact sheet 12234, June 2026: Medicare.gov
14. Medicare GLP-1 Bridge: Centers for Medicare and Medicaid Services
15. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab, 2025
16. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025

This article is for education only and is not medical advice. It summarizes the FDA labels and published research and gives no personalized dosing advice. Talk to your prescriber before starting, stopping, or switching either medicine. Read our full medical disclaimer.